Tempus AI’s (TEM) “Buy” Rating Reaffirmed at Guggenheim

Tempus AI (NASDAQ:TEM)‘s stock had its “buy” rating reiterated by equities researchers at Guggenheim in a report released on Tuesday,Benzinga reports.

Other equities research analysts have also issued reports about the stock. Loop Capital lowered their price target on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Bank of America lifted their target price on Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Needham & Company LLC lifted their price objective on Tempus AI from $56.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday. Piper Sandler reiterated a “neutral” rating and issued a $70.00 price target (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Finally, JPMorgan Chase & Co. cut shares of Tempus AI from an “overweight” rating to a “neutral” rating and boosted their target price for the stock from $50.00 to $55.00 in a research note on Tuesday. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Tempus AI presently has a consensus rating of “Moderate Buy” and an average price target of $60.55.

Tempus AI Stock Performance

TEM stock traded down $9.86 during mid-day trading on Tuesday, hitting $59.72. 13,166,756 shares of the company were exchanged, compared to its average volume of 14,501,441. Tempus AI has a 1-year low of $22.89 and a 1-year high of $91.45. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The firm’s 50 day simple moving average is $50.88 and its 200 day simple moving average is $52.03.

Insiders Place Their Bets

In other news, major shareholder Bradley A. Keywell sold 395,800 shares of Tempus AI stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the completion of the transaction, the insider now directly owns 16,164,449 shares in the company, valued at approximately $694,263,084.55. This trade represents a 2.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David R. Epstein sold 620 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $41.81, for a total transaction of $25,922.20. Following the completion of the transaction, the director now owns 27,894 shares in the company, valued at approximately $1,166,248.14. The trade was a 2.17 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 2,583,467 shares of company stock valued at $130,542,311 over the last quarter.

Institutional Investors Weigh In On Tempus AI

Several institutional investors have recently modified their holdings of TEM. Wells Fargo & Company MN grew its position in Tempus AI by 13.2% in the 4th quarter. Wells Fargo & Company MN now owns 2,384 shares of the company’s stock worth $80,000 after purchasing an additional 278 shares during the period. First Horizon Advisors Inc. bought a new position in Tempus AI in the third quarter valued at about $30,000. Geode Capital Management LLC boosted its position in Tempus AI by 0.4% in the third quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock worth $7,537,000 after purchasing an additional 539 shares during the last quarter. Operose Advisors LLC bought a new stake in shares of Tempus AI during the 4th quarter valued at about $25,000. Finally, Prestige Wealth Management Group LLC increased its position in shares of Tempus AI by 910.4% during the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after purchasing an additional 965 shares during the last quarter. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.